In 2019.0 J MED CHEM published article about FUNCTIONAL SELECTIVITY; REPERFUSION INJURY; RESOLUTION; TARGET in [Baell, Jonathan B.] Nanjing Tech Univ, Sch Pharmaceut Sci, Nanjing 211816, Jiangsu, Peoples R China; [Deora, Girdhar Singh; Debono, Aaron J.; Priebbenow, Daniel L.; Brady, Ryan M.; Beveridge, Julia; Teguh, Silvia C.; Baell, Jonathan B.] Monash Univ, Monash Inst Pharmaceut Sci, Med Chem, Parkville, Vic 3052, Australia; [Qin, Cheng Xue; Vecchio, Elizabeth A.; Minh Deo; Krippner, Guy; Ritchie, Rebecca H.] Baker Heart & Diabet Inst, 7S Commercial Rd, Melbourne, Vic 3004, Australia; [Qin, Cheng Xue; Ritchie, Rebecca H.] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic 3010, Australia; [May, Lauren T.] Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol, Parkville, Vic 3052, Australia; [Ritchie, Rebecca H.] Monash Univ, Dept Diabet, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Baell, Jonathan B.] Monash Univ, ARC Ctr Fragment Based Design, Parkville, Vic 3052, Australia in 2019.0, Cited 21.0. The Name is 2,5-Dimethoxybenzaldehyde. Through research, I have a further understanding and discovery of 93-02-7. COA of Formula: C9H10O3
Herein we describe the development of a focused series of functionalized pyridazin-3(2H)-one-based formyl peptide receptor (FPR) agonists that demonstrate high potency and biased agonism. The compounds described demonstrated biased activation of prosurvival signaling, ERK1/2 phosphorylation, through diminution of the detrimental FPR1/2-mediated intracellular calcium (Ca-i(2+)) mobilization. Compound 50 showed an EC50 of 0.083 mu M for phosphorylation of ERK1/2 and an approximate 20-fold bias away from Ca-i(2+) mobilization at the hFPR1.
Welcome to talk about 93-02-7, If you have any questions, you can contact Deora, GS; Qin, CX; Vecchio, EA; Debono, AJ; Priebbenow, DL; Brady, RM; Beveridge, J; Teguh, SC; Deo, M; May, LT; Krippner, G; Ritchie, RH; Baell, JB or send Email.. COA of Formula: C9H10O3
Reference:
Isothiazole – Wikipedia,
,Isothiazole – ScienceDirect.com